F. Tsai

发表

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

J. Chang, T. Tsou, C. Kuo, 2007, British Journal of Cancer.

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

C. Sima, A. Heguy, N. Katabi, 2013, Cancer.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

F. Janku, D. Rasco, A. Patnaik, 2018, Cancer Chemotherapy and Pharmacology.

188 POSTER Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity

J. Chang, T. Tsou, C. Kuo, 2006 .

32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts

Martha, Rizvi, Mingchao Xie, 2017, Journal of Immunotherapy for Cancer.

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

A. Tolcher, K. Kelly, M. Khasraw, 2021, Journal for ImmunoTherapy of Cancer.

First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Michael Gordon, Jedd D. Wolchok, Anna M. Wu, 2019, The Journal of Nuclear Medicine.

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

K. Morrissey, F. Hodi, P. LoRusso, 2017 .

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

L. Chow, J. Infante, L. Siu, 2016 .

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.

K. Papadopoulos, M. Bennett, S. Fu, 2017 .

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

K. Papadopoulos, A. Fasolo, A. Naing, 2019, Annals of Oncology.

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, J. Infante, D. Rathkopf, 2019, Journal of Clinical Oncology.

An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).

N. Agarwal, D. Rathkopf, L. Rosen, 2018 .

Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.

Xin-Yun Huang, K. Jhaveri, D. D. Hoff, 2021 .

Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.

J. Wolchok, R. Korn, Jason S. Lewis, 2018 .

Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).

J. Nemunaitis, N. Segal, A. Razak, 2018 .

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

Meng Li, M. Maitland, J. Berlin, 2021 .

Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer

T. Powles, S. Salas, A. Balar, 2018, Clinical Trials.

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

F. Janku, G. Bollag, G. Tarcic, 2020 .